CHICAGO — Gilead and Merck made a strong case for combining Trodelvy and Keytruda in the first-line setting for an aggressive form of breast cancer. The combination of Trodelvy and Keytruda reduced the risk of disease …
- BioNTech and BMS partner to advance oncology deal worth over $10 billion June 3, 2025
- R&D and tech innovation boosting biopharmaceutical market to 2030 June 2, 2025
- Roche reports long-term capabilities of multiple sclerosis drug May 30, 2025
- New technology could enhance CAR T therapy manufacture May 29, 2025
- New Eli Lilly acquisition to progress potential next-generation pain treatment May 28, 2025
- CHMP meeting highlights – May 2025 May 27, 2025
- Samsung Bioepis Secures Marketing Approval in Korea for its Biosimilar to Amgen’s Bone Cancer Drug Xgeva June 3, 2025
- EMA Issues Positive CHMP Opinions for Fresenius Denosumab Biosimilars June 2, 2025
- Celltrion, Samsung Bioepis, and Organon Receive Interchangeability Designations for Adalimumab Biosimilars June 2, 2025
- FDA Approves Bio-Thera and Hikma’s Ustekinumab Biosimilar May 29, 2025
- FDA Approves BLA for Novavax’s COVID-19 Vaccine May 23, 2025
- Pharmacist Salaries and Employment in 2024: Retail Employment Collapse Offset by Hospital Boom June 3, 2025
- Three Ways GoodRx Is Helping Pharmacies Increase Profitability and Drive Innovation May 30, 2025
- Drug Channels News Roundup, May 2025: MFN Controversy, Plan Sponsors ♥️ Rebates, PBM Profits, and Fun in Congress May 28, 2025
- How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs May 21, 2025
- What’s Next for Retail Pharmacy: Data, Debate, and Disruption (NEW Live Video Webinar) May 20, 2025
- Resetting the Walk-Away Price: How GoodRx Data Reveals New Realities of Prescription Abandonment May 16, 2025
- How Large PBMs Make Money Today: A 2025 Drug Channels Update May 13, 2025